Cethromycin - Advanced Life Sciences/ Abbott Laboratories
Alternative Names: A-195773; A-195773-0; Abbott-195773; ABT 773; RestanzaLatest Information Update: 06 May 2011
At a glance
- Originator Abbott Laboratories
- Developer Abbott Laboratories; Advanced Life Sciences; National Institute of Allergy and Infectious Diseases; Taisho Pharmaceutical; United States Army Medical Research Institute of Infectious Diseases; Walter Reed Army Institute of Research
- Class Antibacterials; Ketolides
- Mechanism of Action Protein 50S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Suspended Anthrax; Community-acquired pneumonia; Gonorrhoea; Malaria; Melioidosis; Plague; Tularaemia
- Discontinued Acute sinusitis; Bacterial infections; Clostridium difficile infections; Toxoplasmosis
Most Recent Events
- 06 May 2011 Suspended - Phase-III for Community-acquired pneumonia in Canada (PO)
- 06 May 2011 Suspended - Phase-III for Community-acquired pneumonia in Europe (PO)
- 06 May 2011 Suspended - Phase-III for Community-acquired pneumonia in Israel (PO)